Public
American Hospital Association content that is available to the public and all website users.
In October, 2020, a significant number of vulnerabilities in common information systems relevant to the healthcare sector have been disclosed to the public.
In this edition, Hacking Healthcare takes a look at how industry conferences and networking sites are fertile grounds for cyberattacks. Next, we briefly explore a concerning threat advisory jointly posted by three federal government agencies on October 28th that warned of imminent cyberattacks…
Existing hospital or community based infusion centers
Existing clinical space (e.g. urgent care, emergency depts)
Ad hoc new infusion sites (e.g. "hospitals without walls”)
Initial version of playbook focused on:
Mandiant recently elevated a tracked threat cluster to the named threat group FIN11. Beginning in 2016 with phishing campaigns, this group has moved into double extortion ransomware operations utilizing CLOP ransomware.
The AHA on Friday sent a letter to the Health Resources and Services Administration’s Office of Pharmacy Affairs urging the agency to order drug manufacturers and their vendor Kalderos to immediately halt their conversion of the 340B program to a back-end rebate program.
AHA comments on the Centers for Medicare & Medicaid Services’ proposed revision to the definition of “reasonable and necessary” for purposes of Medicare coverage determinations. View entire comment letter under Key Resources.
AHA letter urging the Centers for Medicare & Medicaid Services to immediately withdraw the new condition of participation that threatens to expel hospitals from the Medicare program if they fail to comply with “frequently changing and confusing” COVID-19 data collection efforts.
In anticipation of the likely issuance of emergency use authorizations (EUAs) for at least two monoclonal antibody therapeutic drugs developed to treat certain COVID-19 positive patients, providers should begin planning for the distribution and administration process of these therapeutics.
In a letter to Senator Lamar Alexander and Representative Greg Walden, AHA expresses strong support for the 340B Drug Pricing Program.